Heads up, Biogen. After digging into Tecfidera patent arguments, analyst predicts a loss
As Biogen preps for its closely watched aducanumab FDA filing in Alzheimer’s disease, a patent threat for the company’s top-selling medicine is causing concern for one team of analysts. In a note to clients Tuesday, Bernstein analyst Ronny Gal and his team downgraded Biogen’s stock—from outperform to market-perform—based on the belief that Mylan will win… Read More »